VitaNova Life Sciences Corporation VNOV
OTC PK
| 07/31/2026 | 04/30/2026 | 01/31/2026 | 10/31/2025 | 07/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 3.24M | 3.03M | 3.19M | 2.79M | 2.66M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.24M | 3.03M | 3.19M | 2.79M | 2.66M |
| Cost of Revenue | 2.37M | 2.11M | 1.39M | 1.12M | 1.09M |
| Gross Profit | 872.30K | 910.60K | 1.80M | 1.68M | 1.57M |
| SG&A Expenses | 958.40K | 906.90K | 607.50K | 418.30K | 349.90K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.33M | 3.02M | 2.00M | 1.53M | 1.44M |
| Operating Income | -86.20K | 3.60K | 1.20M | 1.26M | 1.22M |
| Income Before Tax | -83.20K | 6.60K | 1.19M | 1.26M | 1.22M |
| Income Tax Expenses | 31.00K | 44.00K | 448.90K | 393.10K | 357.70K |
| Earnings from Continuing Operations | -0.11 | -0.04 | 0.75 | 0.86 | 0.86 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -114.20K | -37.40K | 745.40K | 862.80K | 859.60K |
| EBIT | -86.20K | 3.60K | 1.20M | 1.26M | 1.22M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.01 | 0.00 | 0.09 | 0.10 | 0.10 |
| Normalized Basic EPS | -0.01 | 0.00 | 0.09 | 0.09 | 0.09 |
| EPS Diluted | -0.01 | 0.00 | 0.09 | 0.10 | 0.10 |
| Normalized Diluted EPS | -0.01 | 0.00 | 0.09 | 0.09 | 0.09 |
| Average Basic Shares Outstanding | 33.35M | 33.35M | 33.35M | 33.35M | 33.35M |
| Average Diluted Shares Outstanding | 33.35M | 33.35M | 33.35M | 33.35M | 33.35M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |